Background: Constitutional delay of growth and puberty (CDGP) is one of the most common problems in pediatrics. It causes a lot of psychological and social disorders in families. Currently, there are a variety of therapies including administration of testosterone enantate, oxandrolone and growth hormone available.The aim of this study, which has been performed for the first time in Iran and the second in the world, was to compare the effect of oral iron in combination with vitamin A with that of oxandrolone in promoting height growth and bone age of children with CDGP. HSDS, WSDS, BMI, SMR, bone age and serum IGF-1 levels were used as milestones of such improvement in this study.Methods: This clinical trial was performed on 85 CDGP boys. After registration of personal identities and taking blood, urine and stool specimens, to rule out probable underlying diseases and interfering factors, children were divided into three groups including a control group, those treated with oxandrolone and those treated with oral iron and vitamin A. Data were transferred to SPSS program where the results were analyzed by paired T-, ANOVA, Tukey, and Wilkakson – Krueskwalis tests.Findings: There was no significant difference between the treated groups in HSDS (p= 0.56), WSDS (p = 0.08) and BMI (p= 0.51). On the other hand, there was a significant difference in SMR (p< 0.001) and bone age (p< 0.001) between groups. Eventually, no significant difference was found in serum IGF-1 levels between the two treated groups (p= 0.98).Conclusion: Iron and vitamin A can be used instead of oxandrolone in CDGP children with the same therapeutic effects and without the adverse effects seen with oxandrolone administration. In addition, this new therapeutic method has no significant effect on SMR and bone age promotion in contrast with oxandrolone therapy.